These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18521540)

  • 1. Selective thromboxane inhibition after vascular protectant AGI-1067: results of assessment of lipoprotein profiles (ALPS) biomarkers in vitro and in vivo substudy.
    Serebruany V; Malinin A; Qiu FH; Xu XC; Kunsch C; Scott R;
    J Thromb Thrombolysis; 2009 May; 27(4):438-46. PubMed ID: 18521540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy.
    Serebruany VL; Glassman AH; Malinin AI; Nemeroff CB; Musselman DL; van Zyl LT; Finkel MS; Krishnan KR; Gaffney M; Harrison W; Califf RM; O'Connor CM;
    Circulation; 2003 Aug; 108(8):939-44. PubMed ID: 12912814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
    Serebruany VL; Malinin A; Eisert C; Ong S
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):635-41. PubMed ID: 17605642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The in vitro effects of a novel vascular protectant, AGI-1067, on platelet aggregation and major receptor expression in subjects with multiple risk factors for vascular disease.
    Serebruany V; Malinin A; Scott R
    J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):191-6. PubMed ID: 17056832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects.
    Bode-Böger SM; Böger RH; Schubert M; Frölich JC
    Eur J Clin Pharmacol; 1998; 54(9-10):707-14. PubMed ID: 9923572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical results with AGI-1067: a novel antioxidant vascular protectant.
    Tardif JC
    Am J Cardiol; 2003 Feb; 91(3A):41A-49A. PubMed ID: 12645643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression.
    Serebruany VL; Suckow RF; Cooper TB; O'Connor CM; Malinin AI; Krishnan KR; van Zyl LT; Lekht V; Glassman AH;
    Am J Psychiatry; 2005 Jun; 162(6):1165-70. PubMed ID: 15932816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of lipoprotein profiles study (ALPS) and antioxidant activity in healthy subjects treated with AGI-1067.
    Davidson MH; Smith J; Scott R; Small R; Choi J; Ishida BY; Kane JP;
    J Clin Lipidol; 2007 Aug; 1(4):271-9. PubMed ID: 21291691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of AGI-1067 and probucol after percutaneous coronary interventions.
    Tardif JC; Grégoire J; Schwartz L; Title L; Laramée L; Reeves F; Lespérance J; Bourassa MG; L'Allier PL; Glass M; Lambert J; Guertin MC;
    Circulation; 2003 Feb; 107(4):552-8. PubMed ID: 12566365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic prevention of both restenosis and atherosclerosis progression: AGI-1067, probucol, statins, folic acid and other therapies.
    Tardif JC; Grégoire J; Lavoie MA; L'Allier PL
    Curr Opin Lipidol; 2003 Dec; 14(6):615-20. PubMed ID: 14624139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration.
    Hedegaard SS; Hvas AM; Grove EL; Refsgaard J; Rocca B; Daví G; Kristensen SD
    Thromb Res; 2009 May; 124(1):96-100. PubMed ID: 19215971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of restenosis with antioxidants: mechanisms and implications.
    Tardif JC; Grégoire J; L'Allier PL
    Am J Cardiovasc Drugs; 2002; 2(5):323-34. PubMed ID: 14727962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary excretion of thromboxane and prostacyclin metabolites during chronic low-dose aspirin: evidence for an extrarenal origin of urinary thromboxane B2 and 6-keto-prostaglandin F1 alpha in healthy subjects.
    Chiabrando C; Rivoltella L; Martelli L; Valzacchi S; Fanelli R
    Biochim Biophys Acta; 1992 Feb; 1133(3):247-54. PubMed ID: 1737057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: a novel antioxidant and anti-inflammatory agent.
    Kunsch C; Luchoomun J; Grey JY; Olliff LK; Saint LB; Arrendale RF; Wasserman MA; Saxena U; Medford RM
    J Pharmacol Exp Ther; 2004 Mar; 308(3):820-9. PubMed ID: 14617690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AGI-1067: a novel vascular protectant for prevention of restenosis.
    Franks AM; Gardner SF
    Ann Pharmacother; 2006 Jan; 40(1):66-73. PubMed ID: 16303986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial.
    Tardif JC; Grégoire J; L'Allier PL; Ibrahim R; Anderson TJ; Reeves F; Title LM; Schampaert E; LeMay M; Lespérance J; Scott R; Guertin MC; Brennan ML; Hazen SL; Bertrand OF;
    Atherosclerosis; 2008 Mar; 197(1):480-6. PubMed ID: 17214993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostacyclin and thromboxane in diabetic children.
    Kaar ML; Kaapa P; Viinikka L; Ylikorkala O
    Prostaglandins Leukot Med; 1983 Jul; 11(3):339-44. PubMed ID: 6351104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of glibenclamide on serum lipids, lipoproteins, thromboxane, beta-thromboglobulin, and prostacyclin in non-insulin-dependent diabetes mellitus.
    Waysbort J; Regitz G; Chaimowitz D; Tuval M; Nakash I; Brunner D
    Clin Ther; 1988; 10(4):358-71. PubMed ID: 2978874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of vacuum curettage on the concentrations of plasma 6-keto-prostaglandin F1 alpha and serum thromboxane B2.
    Ylikorkala O; Mäkilä UM; Viinikka L
    Br J Obstet Gynaecol; 1983 Mar; 90(3):251-4. PubMed ID: 6338904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent.
    Sundell CL; Somers PK; Meng CQ; Hoong LK; Suen KL; Hill RR; Landers LK; Chapman A; Butteiger D; Jones M; Edwards D; Daugherty A; Wasserman MA; Alexander RW; Medford RM; Saxena U
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1116-23. PubMed ID: 12626663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.